Trial Search Results

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

To provide Therasphere treatment for patients diagnosed with unresectable liver cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: BTG International Inc.


  • Device: Therasphere


Inclusion Criteria:

Patients of any age, of any race or sex, who have hepatocellular carcinoma of the liver,
and who are able to give informed consent, will be eligible. Patients must have an ECOG
Performance Status score of /= 3 months, non-pregnant
with an acceptable contraception in premenopausal women. Patients must be >4 weeks since
prior radiation or prior surgery and at least 1 month post other chemotherapy.

Exclusion Criteria:

   - Contraindications to angiography and selective visceral catheterization

   - Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of
   radiation to the lungs

   - Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after
   application of established angiographic techniques to stop or mitigate such flow (ex.
   placing catheter distal to gastric vessels)

   - Significant extrahepatic disease representing an imminent life-threatening outcome

   - Severe liver dysfunction or pulmonary insufficiency

   - Active uncontrolled infection

   - Significant underlying medical or psychiatric illness

   - Pregnancy

Patients will be excluded: if they have a co-morbid disease or an acute or chronic
condition that would preclude safe delivery of TheraSphere treatment and place the patient
at undue risk.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amy Macke